BetterLife Pharma to Host Investors Update Call on September 18, 2023

• Post published:September 14, 2023
• Post category:Press Release

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001

• Post published:September 12, 2023
• Post category:Press Release

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement

• Post published:September 5, 2023
• Post category:Press Release

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement

• Post published:July 13, 2023
• Post category:Press Release

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

• Post published:June 27, 2023
• Post category:Press Release

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

• Post published:June 22, 2023
• Post category:Press Release

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

• Post published:June 8, 2023
• Post category:Press Release

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

• Post published:April 25, 2023
• Post category:Press Release

BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

• Post published:April 20, 2023
• Post category:Press Release

BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article

• Post published:March 29, 2023
• Post category:Press Release